Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily

Respiratory Medicine

Volumn 102, Issue 4, 2008, Pages 495-504

  Kerwin, Edward M ^a   Nathan, Robert A ^b   Meltzer, Eli O ^c   Ortega, Hector G ^d   Yancey, Steven W ^d   Schoaf, Lynne ^d   Dorinsky, Paul M ^d  

^a Clinical Research Institute of Southern Oregon   (United States)

^b Asthma & Allergy Associates PC and Research Center   (United States)

^c Medical Center   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Fluticasone propionate; Inhaled corticosteroid; Long acting beta2 agonist; Once daily; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE; HYDROCORTISONE; SALBUTAMOL; SALMETEROL;

ACUTE CHOLECYSTITIS; ADULT; ARTICLE; ASTHMA; BACKACHE; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EVENING DOSAGE; FEMALE; FLANK PAIN; GLIOBLASTOMA; HEADACHE; HEART ATRIUM FIBRILLATION; HOARSENESS; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLUENZA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROLITHIASIS; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SORE THROAT; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOMATOLOGY; THRUSH; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; METERED DOSE INHALERS; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; SAFETY; TREATMENT OUTCOME;

EID: 40049096608     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.12.002     Document Type: Article

References (30)

1. Expert Panel Report III Full Report Update 2007. National asthma education and prevention program expert panel report: guidelines for the diagnosis and management of asthma availiable at 〈http://www.nhlbi.nih.gov/guidelines/asthma/index.htm〉.
2. Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. Revised 2006. Available from: 〈www.ginasthma.org〉. Accessed July 12, 2007.
3. Nathan R., Li J., Finn A., et al. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 118 (2000) 296-302
4. Wolfe J., Rooklin A., Grady J., et al. Comparison of once- and twice-daily dosing of fluticasone propionate 200 mcg per day administered by DISKUS device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol 105 (2000) 1153-1161
5. ZuWallack R., Adelglass J., Clifford D., et al. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 118 (2000) 303-312
6. Berger W.E., Ford L.B., Mahr T., et al. Efficacy and safety of fluticasone propionate 250 mcg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids. Ann Allergy Asthma Immunol 89 (2002) 393-399
7. Purucker M., Rosebraugh C., Zhou F., et al. Inhaled fluticasone propionate by Diskus in the treatment of asthma a comparison of the efficacy of the same nominal dose given either once or twice daily. Chest 124 (2003) 1584-1593
8. Bootsma G.P., Dekhuijen P.N.R., Festen J., et al. Sustained protection against distilled water provocation by a single dose of salmeterol in patients with asthma. Eur Respir J 10 (1997) 2230-2236
9. Faurschou P., Engel A.-M., and Haannaes O.C. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 49 (1994) 827-832
10. Cartier A., Ghezzo H., L'Archeveque J., Trudeau C., and Malo J.L. Duration and magnitude of action of 50 and 100 micrograms of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma. J Allergy Clin Immunol 92 (1993) 488-492
11. Kemp J.P., Bierman C.W., and Cocchetto D.M. Dose-response study of inhaled salmeterol in asthmatic patients with 24-h spirometry and Holter monitoring. Ann Allergy 70 (1993) 316-322
12. Rabe K.F., Jorres R., Nowak D., et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 h in bronchial asthma. Am Rev Respir Dis 147 (1993) 1436-1441
13. Pincus D.J., Humeston T.R., and Martin R.J. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 100 (1997) 771-774
14. Chisholm S.L., Dekker F.W., Neven A.K., and Petri H. Once-daily budesonide in mild asthma. Respir Med 92 (1998) 421-425
15. Weiner P., Weiner M., and Azgad Y. Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Thorax 50 (1995) 1270-1273
16. Jones A.H., Langdon C.G.F., Lee P.S., et al. Pulmicort Turbuhaler once daily as initial prophylactic therapy for asthma. Respir Med 88 (1994) 293-299
17. Herjavecz I., Blomqvist P., and Serrano A. Efficacy of once- and twice-daily administration of budesonide via Turbuhaler as initial therapy in patients with persistent asthma. Respir Med 93 (1999) 230-235
18. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136 (1987) 225-244
19. ® system. 2nd ed (2000), SAS Institute Inc., Cary, NC p. 170-1
20. Chambers C.V., Markson L., Diamond J.J., et al. Health beliefs and compliance with inhaled corticosteroids by asthmatic patients in primary care practices. Respir Med 93 (1999) 88-93
21. Cochrane G.M., Horne R., and Chanez P. Compliance in asthma. Respir Med 93 (1999) 763-769
22. Rand C.S., Nidies M., Cowles M.K., et al. Long-term metered-dose inhaler adherence in a clinical trial. Am J Respir Crit Care Med 152 (1995) 580-588
23. Nelson H.S., Beasley R., Yancey S.W., et al. No increase in asthma-related hospitalizations following the addition of salmeterol to an inhaled corticosteroid in patients with asthma: a meta-analysis. Am J Respir Crit Care Med 175 (2007) A59
24. Stoloff S.W., Stempel M.A., Meyer J., et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 113 (2004) 245-251
25. Stempel D.A., Stoloff S.W., Rosenzweig J.R.C., et al. Adherence to asthma controller medication regimens. Respir Med 99 (2005) 1263-1267
26. Masoli M., Weatherall M., Ayling J., et al. The 24 h duration of bronchodilator action of the salmeterol/fluticasone combination inhaler. Respir Med 99 (2005) 545-552
27. Aldington S., Williams M., Weatherall M., and Beasley R. Duration of action of the salmeterol/fluticasone combination inhaled administered in the evening. A randomized controlled trial in childhood asthma. Respirology 11 (2006) 638-642
28. Buhl R., Creemers J., Vondra V., et al. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 97 (2003) 323-330
29. Kuna P., Creemers J., Vondra V., et al. Once-daily budesonide/formoterol compared with twice-daily budesonide/formoterol and once daily budesonide in adults with mild to moderate asthma. Respir Med 100 (2006) 2151-2159
30. Peters S., Anthonisen N., Castro M., et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 356 (2007) 2027-2039